<DOC>
	<DOCNO>NCT00559182</DOCNO>
	<brief_summary>This first-in-human trial establish safety , tolerability , Recommended Phase II Dose ( RP2D ) , pharmacodynamic , clinical activity MK-8033 . Parts A B study determine maximum tolerate dose ( MTD ) RP2D . Part C study single panel crossover study determine effect omeprazole , gastric pH modifier , pharmacokinetics MK-8033 .</brief_summary>
	<brief_title>A Study MK-8033 Patients With Advanced Solid Tumors ( MK-8033-001 )</brief_title>
	<detailed_description />
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Patient must least 18 year age , adequate organ function , Eastern Cooperative Oncology Group ( ECOG ) performance &lt; 2 Patient must willing undergo prestudy postdose tumor biopsy tumor accessible biopsy ( Waived Parts A C ) Patient currently use bisphosphonate therapy receive therapy past 6 month Patient chemotherapy , radiotherapy , biological therapy within 4 week study participation Patient history cardiac disease Patient primary central nervous system tumor Patient know psychiatric substance abuse disorder Patient pregnant breastfeeding , expect conceive study Patient know Human Immunodeficiency Virus ( HIV ) positive HIV infection well control Patient receive therapy ProtonPump Inhibitor , Histamine2Receptor antagonist antacid within one week study participation ( Part B )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>